Chengda Pharmaceuticals Hits Day Low of CNY 35.77 Amid Price Pressure

Chengda Pharmaceuticals Co., Ltd. experienced a significant decline today, with the stock dropping by 7.66% as it reached an intraday low of CNY 35.77. This performance stands in contrast to the China Shanghai Composite, which saw a slight increase of 0.04% on the same day. Over the past week, Chengda's stock has decreased by 2.64%, while its performance over the last month shows a notable increase of 18.07%. However, year-to-date, the stock has faced challenges, with a decline of 12.04%. In the longer term, the stock has demonstrated resilience, achieving a 41.33% increase over the past three years, significantly outperforming the China Shanghai Composite's 26.26% growth during the same period. Despite these fluctuations, the company has reported positive quarterly results, including a pre-tax profit growth of 417.99% and a net profit increase of 354.71%. However, concerns remain regarding management efficiency, as indicated by a low return on capital employed of 7.29%. Overall, Chengda Pharmaceuticals continues to navigate a complex market landscape within the pharmaceuticals and biotechnology sector.